Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Regeneron Pharmaceuticals Inc (OQ:REGN)

Business Focus: Bio Therapeutic Drugs

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 777 Old Saw Mill River Road
TARRYTOWN NY 10591
Tel: N/A
Website: https://www.regeneron.com
IR: See website
Key People
Leonard S. Schleifer
Co-Chairman of the Board, President, Chief Executive Officer, Founder
George D. Yancopoulos
Co-Chairman of the Board, President, Chief Scientific Officer
Christopher R. Fenimore
Chief Financial Officer, Senior Vice President - Finance
Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Marion E. McCourt
Executive Vice President - Commercial
Andrew J. Murphy
Executive Vice President - Research
Neil Stahl
Executive Vice President - Research and Development
Jason Pitofsky
Vice President, Controller
Business Overview
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, hematologic conditions, infectious diseases, and rare diseases. It helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; REGEN-COV; Kevzara (sarilumab) Injection, and others.
Financial Overview
For the fiscal year ended 31 December 2023, Regeneron Pharmaceuticals Inc revenues increased 8% to $13.12B. Net income decreased 9% to $3.95B. Revenues reflect Sanofi segment increase of 33% to $3.8B, Libtay-ROW segment increase from $73M to $324.3M. Net income was offset by Selling, general increase of 25% to $2.32B (expense), Research and development increase of 21% to $2.41B (expense).